ARS Pharmaceuticals, Inc. (SPRY)
Largest Insider Buys in Sector
SPRY Stock Price History Chart
SPRY Stock Performance
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Insider Activity of ARS Pharmaceuticals, Inc.
Over the last 12 months, insiders at ARS Pharmaceuticals, Inc. have bought $13.29M and sold $94.29M worth of ARS Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at ARS Pharmaceuticals, Inc. have bought $25.62M and sold $32.63M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $398.68M.
The last purchase of 505,954 shares for transaction amount of $4.95M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑03‑27.
List of Insider Buy and Sell Transactions, ARS Pharmaceuticals, Inc.
| 2025-01-06 | Sale | director | 50,000 0.0511% | $11.10 | $555,065 | +2.44% | ||
| 2024-12-17 | Sale | CHIEF MEDICAL OFFICER | 100,000 0.1035% | $11.67 | $1.17M | -4.93% | ||
| 2024-12-17 | Sale | PRESIDENT AND CEO | 100,000 0.1035% | $11.67 | $1.17M | -4.93% | ||
| 2024-12-13 | Sale | Chief Business Officer | 27,272 0.0282% | $12.06 | $328,969 | -5.97% | ||
| 2024-12-12 | Sale | Chief Business Officer | 117,333 0.1186% | $12.27 | $1.44M | -11.43% | ||
| 2024-12-12 | Sale | Chief Operating Officer | 25,000 0.0253% | $12.30 | $307,433 | -11.43% | ||
| 2024-12-11 | Sale | Chief Operating Officer | 15,000 0.0154% | $12.43 | $186,426 | -8.72% | ||
| 2024-12-10 | Sale | CHIEF MEDICAL OFFICER | 100,000 0.1038% | $13.16 | $1.32M | -13.28% | ||
| 2024-12-10 | Sale | PRESIDENT AND CEO | 100,000 0.1038% | $13.16 | $1.32M | -13.28% | ||
| 2024-12-10 | Sale | Chief Business Officer | 50,000 0.0519% | $13.15 | $657,625 | -13.28% | ||
| 2024-12-06 | Sale | Chief Business Officer | 50,000 0.0517% | $14.23 | $711,615 | -19.40% | ||
| 2024-12-05 | Sale | Chief Business Officer | 49,640 0.0521% | $14.13 | $701,642 | -19.00% | ||
| 2024-12-04 | Sale | director | 14,772 0.0146% | $13.75 | $203,109 | -21.29% | ||
| 2024-12-04 | Sale | Chief Business Officer | 45,000 0.0452% | $13.95 | $627,944 | -21.29% | ||
| 2024-12-04 | Sale | Chief Commercial Officer | 6,283 0.0063% | $14.00 | $87,962 | -21.29% | ||
| 2024-12-03 | Sale | director | 87,984 0.0888% | $13.26 | $1.17M | -16.53% | ||
| 2024-12-03 | Sale | Chief Business Officer | 45,000 0.0452% | $13.19 | $593,402 | -16.53% | ||
| 2024-12-02 | Sale | director | 97,244 0.1019% | $13.56 | $1.32M | -13.21% | ||
| 2024-12-02 | Sale | Chief Business Officer | 45,000 0.0475% | $13.67 | $615,218 | -13.21% | ||
| 2024-12-02 | Sale | Chief Commercial Officer | 3,717 0.0041% | $14.11 | $52,461 | -13.21% |
Insider Historical Profitability
| RA CAPITAL MANAGEMENT, L.P. | 9958073 10.2465% | $12.28 | 5 | 0 | +131.88% | |
| Flynn James E | 10 percent owner | 5257328 5.4096% | $12.28 | 0 | 2 | |
| Lowenthal Richard E | PRESIDENT AND CEO | 1098499 1.1303% | $12.28 | 0 | 30 | |
| Tanimoto Sarina | CHIEF MEDICAL OFFICER | 1098499 1.1303% | $12.28 | 0 | 30 | |
| Shawver Laura | director | 210346 0.2164% | $12.28 | 0 | 18 | |
| Chakma Justin | Chief Business Officer | 136380 0.1403% | $12.28 | 0 | 11 | |
| Dorsey Brian | Chief Operating Officer | 6024 0.0062% | $12.28 | 0 | 4 | |
| Karas Eric | Chief Commercial Officer | 5693 0.0059% | $12.28 | 0 | 4 | |
| Scott Kathleen D. | Chief Financial Officer | 4949 0.0051% | $12.28 | 0 | 2 | |
| ORBIMED ADVISORS LLC | director | 0 0% | $12.28 | 1 | 4 | |
| Thompson Peter A. | director | 0 0% | $12.28 | 1 | 4 | |
| Fitzpatrick Alexander A | Chief Legal Officer | 89227 0.0918% | $12.28 | 2 | 0 | +133.38% |